Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.

Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.

Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.

Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.

Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.

He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.

Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.613
Québec, QC
Canada G1J 1Z4
185 entries « 19 of 19 »

Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure

Journal Article

J Urol, 162 (6), 1999.

Abstract | Links:

Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Tetu B, Meyer F, Fradet Y

Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors

Journal Article

Hum Pathol, 30 (11), 1999.

Abstract | Links:

Lacombe L, Fradet Y

Blood management and radical retropubic prostatectomy: Quebec experience

Journal Article

Can J Urol, 6 (2), 1999.

Abstract | Links:

Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, Meyer F, Fradet Y

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence

Journal Article

Clin Cancer Res, 5 (12), 1999.

Abstract | Links:

Lacombe L, Gauthier J, Lafleur L, Fradet Y

[Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]

Journal Article

Prog Urol, 6 (6), 1996.

Abstract | Links:

185 entries « 19 of 19 »
Signaler des ajouts ou des modifications

Active projects

  • A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma, from 2023-09-22 to 2028-12-25
  • Soutien à la recherche, from 2017-07-01 to 2024-06-30
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31

Recently finished projects

  • Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31
Data provided by the Université Laval research projects registery